A new drug is considered ‘new’ for 10 years instead of the current four and it will be followed from the date of its first approval. A committee of secretaries has proposed that period in the interest of better and more effective regulation. The committee comprising the secretaries of DIPP, health, pharmaceuticals, the CEO of Niti Aayog and a joint secretary in the Prime Minister’s Office (PMO) was formed at the behest of the PMO to look into ways to promote the Indian pharmaceutical industry, to ensure effortlessness quality maintenance.
Regulatory requirements are different and more powerful for new drugs and data on post marketing surveillance (PMS) has to be periodically submitted.
Changing Rule 122E to say ten years instead of four for a new drug gives better opportunity to look out for adverse drug reactions and the matter remains in the domain of the DCGI. After the period specified in Rule 122E is over the state governments give product licences and regulation. It is not final yet and a technical group in the office of the DCGI is working out the final details. Additional information on India’s current process for registering medical devices, cosmetics, IVD’s are available in our blog section.
On February 2, 2017 The Ministry of Health and Family Welfare has announced Medical Devices Rules, 2017 that separates regulatory norms for manufacturing medical devices from drugs. The rules will come into effect from January […]Read More
Maharashtra Food and Drug Administration (FDA) has directed all 306 blood banks in the state to submit applications of renewal of licenses by 31st December 2016 to carry out timely inspections and approvals. There are […]Read More
Indian syringes and needles market is expected to grow at a CAGR of 15% by 2020. This growth is mainly because of India’s large pool of patients, increase in healthcare expenditure, increase in healthcare awareness […]Read More
The Ministry of Health’s Food Safety Standards Authority of India has come out with quality and safety standards to regulate the standards and quality of health supplements, nutraceuticals, food (special dietary care, medicinal purpose, functional […]Read More
On Monday, Indian food safety watchdog the Food Safety and Standards Authority of India (FSSAI) announced that health supplements cannot be sold as medicines at all and also fixed the permissible limits of various ingredients […]Read More
Now a new survey shows that, natural products continue to remain top of mind for many women when it comes to the personal care beauty products. The second annual Green Beauty Barometer survey questioned more […]Read More
The United States remains the biggest market for Korean cosmetic products and nowadays Korean investors are venturing into Indian cosmetic market. The Korea Trade Investment Promotion Agency (KOTRA) launched at least 10 Korean cosmetics brands […]Read More
The first Medical Device Regulatory Summit in India is being held at Holiday Inn Mumbai International Airport on 29 November 2016. Morulaa HealthTech is pleased to partner at this event. Medical Device Regulatory Summit 2016, […]Read More